Literature DB >> 8725679

Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients.

O Ifudu1, E Chan, H Paul, J D Mayers, L S Cohen, W F Brezsnyak, A I Herman, M M Avram, E A Friedman.   

Abstract

Neither the sociodemographic correlates nor the biochemical/clinical consequences of missed dialysis treatments have been well defined. During a 10 week period, the authors enumerated missed dialysis treatments among 430 patients randomly selected from a pool of 1,395 hemodialysis patients. A forward logistic regression model was used to determine whether a relationship existed between missed dialysis treatments and the following independent variables: age, gender, race, renal diagnosis, length of time on maintenance hemodialysis, co-morbidity index, modified Karnofsky score, employment status, household residents, and laboratory indices. Forty-three (10%) of 430 patients missed a total of 96 treatments. Despite equivalent treatment with erythropoietin, patients who missed dialysis treatment(s) had a lower mean hematocrit (27 +/- 4.3%) at the end of the study than those patients who underwent all treatments (29 +/- 4.5%) (p = 0.0287). Mean serum albumin and creatinine levels were equivalent in compliant and noncompliant patients. Recent starts (p = 0.0048), and younger patients (p = 0.0424) were most likely to miss dialysis treatment(s). One of the major consequences of missed dialysis treatment(s) is exacerbation of anemia, and younger patients and freshly started patients are more likely to miss scheduled dialysis treatments than their respective counterparts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725679

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  2 in total

1.  Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.

Authors:  Areef Ishani; Haifeng Guo; Thomas J Arneson; David T Gilbertson; Lih-Wen Mau; Suying Li; Stephan Dunning; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

Review 2.  The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.

Authors:  Janice P Lea; Keith Norris; Lawrence Agodoa
Journal:  Am J Nephrol       Date:  2008-04-24       Impact factor: 3.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.